Unresectable Pleural Mesothelioma
Conditions
Brief summary
overall survival
Detailed description
Overall Survival and Progression Free Survival, OS and PFS at specific landmarks, Overall Response Rate, Duration of Response, and PFS2 (time from randomization to the second progression event)., TTD in physical functioning, change from baseline in disease-related symptoms, and in functioning, Incidence of ADAs against volrustomig., Concentrations of volrustomig and PK parameters as data allow, Safety and tolerability based on AEs, rates of AE-related dose discontinuations/modifications, vital signs, clinical laboratory assessments, physical examinations, and ECGs
Interventions
DRUGIPILIMUMAB
DRUGCARBOPLATIN
DRUGMycofit
DRUG250 mg
DRUGkapsułki twarde
DRUGPEMETREXED
DRUGNIVOLUMAB
DRUGCISPLATIN
DRUGINFLIXIMAB
DRUGvolrustomig
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival and Progression Free Survival, OS and PFS at specific landmarks, Overall Response Rate, Duration of Response, and PFS2 (time from randomization to the second progression event)., TTD in physical functioning, change from baseline in disease-related symptoms, and in functioning, Incidence of ADAs against volrustomig., Concentrations of volrustomig and PK parameters as data allow, Safety and tolerability based on AEs, rates of AE-related dose discontinuations/modifications, vital signs, clinical laboratory assessments, physical examinations, and ECGs | — |
Countries
Belgium, Denmark, France, Germany, Italy, Netherlands, Norway, Poland, Spain
Outcome results
None listed